A detailed history of New York Life Investment Management LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, New York Life Investment Management LLC holds 12,967 shares of PCVX stock, worth $431,152. This represents 0.01% of its overall portfolio holdings.

Number of Shares
12,967
Previous 12,469 3.99%
Holding current value
$431,152
Previous $1.02 Million 52.06%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 08, 2025

BUY
$37.76 - $92.13 $18,804 - $45,880
498 Added 3.99%
12,967 $489,000
Q4 2024

Feb 04, 2025

BUY
$80.97 - $117.93 $39,999 - $58,257
494 Added 4.13%
12,469 $1.02 Million
Q3 2024

Nov 07, 2024

SELL
$70.52 - $117.12 $48,376 - $80,344
-686 Reduced 5.42%
11,975 $1.37 Million
Q2 2024

Aug 05, 2024

BUY
$60.06 - $78.77 $760,419 - $997,306
12,661 New
12,661 $956,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $1.97B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track New York Life Investment Management LLC Portfolio

Follow New York Life Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York Life Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on New York Life Investment Management LLC with notifications on news.